Voya Investment Management LLC Has $12.94 Million Stock Holdings in Alkermes plc (NASDAQ:ALKS)

Voya Investment Management LLC decreased its holdings in Alkermes plc (NASDAQ:ALKS - Free Report) by 3.5% during the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 450,047 shares of the company's stock after selling 16,509 shares during the period. Voya Investment Management LLC owned approximately 0.28% of Alkermes worth $12,943,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Barclays PLC raised its stake in shares of Alkermes by 108.8% in the 3rd quarter. Barclays PLC now owns 423,931 shares of the company's stock valued at $11,867,000 after acquiring an additional 220,893 shares during the period. Wilmington Savings Fund Society FSB purchased a new stake in shares of Alkermes in the third quarter worth about $582,000. Tidal Investments LLC acquired a new stake in shares of Alkermes in the third quarter valued at about $1,098,000. Franklin Resources Inc. raised its holdings in shares of Alkermes by 2.5% during the 3rd quarter. Franklin Resources Inc. now owns 120,006 shares of the company's stock valued at $3,486,000 after buying an additional 2,903 shares during the period. Finally, Diversified Trust Co lifted its position in Alkermes by 11.5% during the 4th quarter. Diversified Trust Co now owns 42,509 shares of the company's stock worth $1,223,000 after acquiring an additional 4,378 shares in the last quarter. 95.21% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on ALKS shares. HC Wainwright reissued a "neutral" rating and set a $46.00 target price on shares of Alkermes in a research report on Thursday, February 13th. Deutsche Bank Aktiengesellschaft raised their target price on Alkermes from $40.00 to $52.00 and gave the company a "buy" rating in a research note on Thursday, March 27th. UBS Group reiterated a "sector perform" rating on shares of Alkermes in a research note on Monday. The Goldman Sachs Group lifted their price objective on Alkermes from $30.00 to $32.00 and gave the stock a "buy" rating in a report on Friday, February 14th. Finally, Royal Bank of Canada reissued an "underperform" rating on shares of Alkermes in a research report on Monday. One analyst has rated the stock with a sell rating, three have issued a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $38.08.

Alkermes Stock Up 6.3 %

Shares of NASDAQ:ALKS traded up $1.81 during trading on Thursday, hitting $30.58. 2,935,372 shares of the company traded hands, compared to its average volume of 1,764,652. The business's fifty day moving average is $31.49 and its 200-day moving average is $30.40. The stock has a market capitalization of $5.04 billion, a price-to-earnings ratio of 14.09, a PEG ratio of 2.20 and a beta of 0.39. Alkermes plc has a one year low of $22.90 and a one year high of $36.45.

Alkermes (NASDAQ:ALKS - Get Free Report) last issued its earnings results on Thursday, May 1st. The company reported $0.13 earnings per share for the quarter, missing the consensus estimate of $0.32 by ($0.19). Alkermes had a return on equity of 30.80% and a net margin of 23.57%. The company had revenue of $306.51 million during the quarter, compared to analyst estimates of $307.53 million. During the same period in the prior year, the business earned $0.43 earnings per share. Alkermes's quarterly revenue was down 12.6% on a year-over-year basis. On average, analysts forecast that Alkermes plc will post 1.31 EPS for the current year.

Insider Transactions at Alkermes

In other Alkermes news, EVP Craig C. Hopkinson sold 144,419 shares of the business's stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $35.53, for a total value of $5,131,207.07. Following the sale, the executive vice president now directly owns 57,875 shares in the company, valued at approximately $2,056,298.75. The trade was a 71.39 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 4.40% of the company's stock.

Alkermes Company Profile

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.